BRIEF published on 11/04/2024 at 11:51, 16 days 23 hours ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 16 days 23 hours ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 month 9 days ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 month 9 days ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 4 months 11 days ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 4 months 11 days ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 6 months 5 days ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 6 months 5 days ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 11/21/2024 at 10:03, 51 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 54 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 54 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 19 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 29 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:30, 24 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 49 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 52 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 54 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 54 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 06:58, 3 hours 56 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 34 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 9 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 9 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
